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The response of cardiomyocytes to biomechanical stress can determine the pathophysiology of hypertrophic
cardiac disease, and targeting the pathways regulating these responses is a therapeutic goal. However, little is
known about how biomechanical stress is sensed by the cardiomyocyte sarcomere to transduce intracellular
hypertrophic signals or how the dysfunction of these pathways may lead to disease. Here, we found that fourand-a-half LIM domains 1 (FHL1) is part of a complex within the cardiomyocyte sarcomere that senses the biomechanical stress–induced responses important for cardiac hypertrophy. Mice lacking Fhl1 displayed a blunted hypertrophic response and a beneficial functional response to pressure overload induced by transverse
aortic constriction. A link to the Gαq (Gq) signaling pathway was also observed, as Fhl1 deficiency prevented
the cardiomyopathy observed in Gq transgenic mice. Mechanistic studies demonstrated that FHL1 plays an
important role in the mechanism of pathological hypertrophy by sensing biomechanical stress responses via
the N2B stretch sensor domain of titin and initiating changes in the titin- and MAPK-mediated responses
important for sarcomere extensibility and intracellular signaling. These studies shed light on the physiological
regulation of the sarcomere in response to hypertrophic stress.
Introduction
Cardiovascular disease and ensuing heart failure is the leading
cause of human morbidity and mortality worldwide. Biomechanical stress–induced growth responses have been shown to play a
pivotal role in the pathophysiology of cardiac disease and could
have application for therapies. However, little is known about how
biomechanical stress is sensed by the cardiomyocyte sarcomere
and transduced into intracellular signals or how dysfunction of
these pathways may lead to disease. Human genetic studies and
genetic mouse models have revealed a structural role for cytoskeletal proteins in the pathophysiology of cardiac disease (1–8).
However, evidence suggests that these proteins may also function
outside their traditional roles in the cardiac cytoskeleton and
have mechanotransduction functions in response to biomechanical stress (4, 5, 9, 10). A central challenge is to define the precise
molecular signals that link these cytoskeletal proteins and their
functions to disease in vivo.
Nonstandard abbreviations used: +dP/dt maximum, maximum positive first derivative of LV pressure as measured over time; –dP/dt maximum, maximum negative first
derivative of LV pressure as measured over time; FHL1, four-and-a-half LIM domains
1; Gq, Gαq; Gq+, Gq gain-of-function transgenic (mice); IVSd, interventricular septal
wall thickness; KO/Gq, Fhl1–/–/Gq transgenic; Lmax, muscle length at which the muscle
develops the maximum force; LV FS, percentage of LV fractional shortening; LVPWd,
LV posterior wall thickness; TAC, transverse aortic constriction.
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. doi:10.1172/JCI34472.

Cytoskeletal proteins from the LIM domain family have been
thought to play a pivotal role in biomechanical stress responses leading to muscle disease (4, 8). The four-and-a-half LIM domains (FHL)
family is a newly identified group of LIM-only proteins named and
structurally characterized by 4 complete LIM domains and an N-terminal half LIM domain (11). FHL1, -2, and -3 are enriched in mammalian striated muscle and associated with multiple binding partners
and biological functions (12, 13), including striated muscle development and function (14). However, the physiological relevance of these
multiple interactions and functions of FHL proteins in vivo remain
unclear. A growing body of evidence has suggested that FHL1 may
play an important role in biomechanical stress responses involved in
cardiac hypertrophy and disease. Recent studies have shown FHL1
as the only FHL member to be upregulated in mouse hearts subsequent to in vivo pressure overload induced hypertrophy and hypertrophic agonists (14, 15). These results are consistent with observations in humans, which show that FHL1 is the only FHL member
that is dramatically increased in hearts of human patients exhibiting
hypertrophic cardiomyopathy (16–18). Based on these findings, we
hypothesized that FHL1 would play an essential role in biomechanical stress–induced cardiac hypertrophy and disease in vivo.
In the present study, we uncovered the role of FHL in the myocardium in vivo by generating and characterizing Fhl1-deficient (Fhl1–/–)
mice. Our studies demonstrate a critical role for FHL1 to sense
biomechanical stress responses important in pathological cardiac
hypertrophy. Using a combination of in vitro and in vivo systems, we
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demonstrate interactions of FHL1 with both sarcomeric (titin N2B)
and signaling (Gαq-MAPK [Gq-MAPK] cascade) components within
the cardiomyocyte and demonstrate the ability of these interactions
to dually affect sarcomere extensibility and hypertrophic signaling responses. Taken together, our studies demonstrate that FHL1
provides an essential connection between the muscle stretch sensor
and downstream titin- and MAPK-mediated responses important
in biomechanical stress responses involved in cardiac hypertrophy.
These studies further shed light on the physiological regulation of
the sarcomere in response to hypertrophic stress.
Results
Generation of Fhl1–/– mice. To examine the role of FHL1 in the myocardium in vivo, we generated Fhl1–/– mice (Figure 1, A and B).
Western blot analysis demonstrated loss of FHL1 but no change
in FHL2 protein expression in adult striated muscle of Fhl1–/– mice
(Figure 1C). Fhl1–/– mice were born at the expected Mendelian ratios
and were viable, with normal life spans. Fhl1–/– hearts exhibited no
differences in cardiac size, dimensions, and function from 8 weeks
(Table 1) to 1 year of age (data not shown) when compared with
WT mice. In addition, no significant differences in blood pressure were observed between WT and Fhl1–/– mice (Supplemental
Table 1; supplemental material available online with this article;
doi:10.1172/JCI34472DS1).
Fhl1–/– mice exhibit a blunted and beneficial response to pressure overload
induced by transverse aortic constriction. Studies have implicated a role
for FHL1 in stress-induced cardiac hypertrophy (14, 16–18). As a
result, we tested the consequences of Fhl1 deficiency in an in vivo
model of pressure overload–induced cardiac hypertrophy caused
by transverse aortic constriction (TAC). Similar trans-stenotic pressure gradients were observed in WT and Fhl1–/– mice following TAC
(Table 1). However, Fhl1–/– hearts were significantly smaller than
those of controls at 1 and 5 weeks after TAC (Figure 1D). This was
reflected in the significantly smaller increase in LV/BW ratio (Figure 1E), cardiomyocyte cross-sectional area (Figure 1F), LV posterior
wall thickness (LVPWd), and interventricular septal wall thickness
(IVSd) (Table 1) in Fhl1–/– hearts compared with those of controls.
A blunted response to hypertrophy was further indicated by the
significantly smaller increase in expression of the fetal gene markers ANF, β-MHC, and skeletal α-actin, known to be re-expressed
following TAC, in Fhl1–/– ventricles compared with those of controls
(Figure 1G). Remarkably, echocardiography demonstrated that
Fhl1–/– mice subjected to TAC were able to maintain the percentage
of LV fractional shortening (LV FS) at levels comparable with those
of sham-operated controls (Table 1), demonstrating preservation of
function in the context of pressure overload. In contrast, controls
exhibited early signs of heart failure, including a significant decrease
in LV FS and increased chamber dilation (increased LV internal
dimension at end diastole [LVIDd] and LV internal dimension at
end-systole), which were clearly apparent 5 weeks after TAC (Table
1). Hemodynamic assessment of Fhl1–/– hearts after long term TAC
revealed a significant preservation in LV end-diastolic pressure and
systolic function as assessed by maximum positive first derivative
of LV pressure as measured over time (+dP/dt maximum), as well as
increased diastolic function as assessed by maximum negative first
derivative of LV pressure as measured over time (–dP/dt maximum)
and relaxation time constant when compared to control mice after
TAC and SHAM controls (Supplemental Table 2).
Genetic ablation of Fhl1 is sufficient to prevent cardiomyopathy in the
Gq transgenic model. Gq signaling plays an essential role in cardiac


hypertrophy induced by agonists in vitro and TAC in vivo (19–21).
To explore possible links between FHL1 and Gq signaling, we first
examined the possibilities that GPCR signaling could regulate
endogenous FHL1 expression in cardiomyocytes. GPCR agonists,
phenylephrine, and angiotensin II, as well as constitutively active
Gq overexpression, significantly increased FHL1 expression in postnatal cardiomyocytes in vitro and in mouse hearts in vivo (Figure
2A). Fhl1–/– mice were bred with the cardiomyopathic Gq transgenic
mice to determine the consequences of Fhl1 deficiency on Gq signaling in the postnatal heart. Fhl1 deficiency completely prevented
the cardiomyopathy in the Gq transgenic mice. Compared with Gq
transgenic ventricles, double Fhl1–/–/Gq transgenic (KO/Gq) hearts
exhibited a significant reduction in LV size, as assessed by LV/BW
ratios and histological assessment of heart size (Figure 2B), as well
as expression of fetal gene markers known to be upregulated with
hypertrophy and stress (Figure 2C). Chamber size (LVIDd), wall
thicknesses (LVPWd, IVSd), and function (LV FS) in KO/Gq transgenic hearts were comparable with WT and Fhl1–/– hearts (Figure
2D). This is in contrast with Gq hearts, which exhibited a significant increase in LVIDd, LVPWd, and IVSd as well as a decrease in LV
FS (Figure 2, B and D), consistent with previous findings (22).
FHL1 associates with MAPK cascade components at the sarcomeric I band.
A recent study has demonstrated that FHL proteins physically associate with the MAPK component, ERK2 (23). Since LIM proteins
can act as scaffolding proteins (13), we sought to determine whether FHL1 could associate with all or certain MAPK components.
Direct interactions between FHL1 and MAPK components were
investigated by yeast 2-hybrid, and interactions were quantified by
β-galactosidase activities (Table 2). Specific interactions between
full-length FHL1 (4.5 LIM) and Raf1, MEK2, and ERK2, but not
MEK1, were observed, suggesting that FHL1 can interact with inactive forms of Raf/MEK/ERK. A specific interaction between FHL1
and a constitutively phosphorylated mutant of ERK2 (i.e., ERK2
[TYDD]) was also observed, suggesting that FHL1 can interact with
active forms of ERK2. Deletion analysis revealed that the first 2 full
LIM domains (FHL1 2 LIM) are essential for the interaction between
FHL1 and Raf1, MEK2, ERK2, and ERK2 (TYDD). In addition, no
interactions could be observed between the small isoform of FHL1
(KyoT2), which is not expressed in the heart (data not shown), and
Raf1, MEK2, ERK2, and ERK2 (TYDD). A link between FHL1 and
the Gq-MAPK was also shown when the MAPK/ERK1 inhibitor,
PD98059, could completely block phenylephrine- and angiotensin
II–mediated upregulation of FHL1 expression in cardiomyocytes
(our unpublished observations).
Coimmunoprecipitation assays were performed on WT mouse
hearts at basal conditions and following TAC to assess the endogenous association of Raf1, MEK1/2, and ERK2 with FHL1. Specific interactions were demonstrated between endogenous FHL1
and Raf1, MEK1/2, and ERK2 in adult mouse hearts, which were
increased following TAC (Figure 3A), consistent with yeast 2-hybrid
studies (Table 1). Immunofluorescence microscopy was further
utilized to assess the localization of FHL1 and Raf/MEK/ERK in
adult cardiomyocytes. Using FHL1 antibodies, which were verified
in Fhl1–/– mice (Figure 1C), as well as sarcomeric antibodies for the
I band (titin N2B) we demonstrated the localization of FHL1 as a
narrow doublet directly colocalizing with titin N2B in adult cardiomyocytes (Figure 3B). To determine whether FHL1 directly binds
to titin N2B, a minimal element of titin N2B (GFP-htitinN2B us3)
that has also been previously shown to bind to FHL2 (24) was generated and assayed for its ability to interact with FHL1 in COS cells.
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Figure 1
Targeted deletion of Fhl1 in mice and its effect on in vivo pressure overload–induced cardiac hypertrophy. (A) Fhl1 genomic region of interest
(top), the targeting construct (center), and the mutated locus after homologous recombination (bottom). B, BamHI; E, EcoRI; E1, exon 1; H,
HindIII; N, NotI; S, StuI; SII, SstII; and X, XhoI. (B) Neo-positive ES cell DNAs were digested with BamHI and analyzed by Southern blotting for
WT (+/y) and targeted (–/y) alleles with the probe shown in A. (C) Protein (20 μg) from WT and Fhl1-deficient (KO) ventricles (8 weeks old) were
subjected to SDS-PAGE to detect FHL1 (~32 kDa) and FHL2 (~34 kDa) expression. EF-1α (~53 kDa) protein was used to normalize for loading.
(D) Paraffin sections from WT and KO hearts following sham (1 week) and TAC operation were stained with hematoxylin and eosin. Scale bar:
2.5 mm. (E) LV weight/BW ratios in WT and KO mice following sham (1 week) and TAC operation. (F) Ventricular sections from WT and KO
mice, following sham (1 week) and TAC operation, stained with wheat germ agglutinin and Hoechst 33342. Original magnification, ×400. Myocyte
cross-sectional areas from at least 200 myocytes per heart in randomly selected fields were assessed. Scale bar: 16 μm. (G) Anf, β-MHC, and
skeletal α-actin RNA expression in WT and KO LVs (n = 4) following sham (1 week) and TAC operation were normalized to Gapdh expression
and presented as fold induction relative to WT sham controls. *P < 0.05; **P < 0.01; ***P < 0.001.
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Table 1
In vivo echocardiographic assessment of cardiac size and function in WT and Fhl1–/– mice following TAC at 1 and 5 weeks
Sham, 1 wk
WT (n = 11)
BW, g
HR, bpm
IVSd, mm
LVIDd, mm
LVIDs, mm
LVPWd, mm
LV FS
TSPG, mmHg

27.1 ± 3.4
511 ± 64
0.75 ± 0.08
3.68 ± 0.44
0.84 ± 0.22
0.75 ± 0.07
46.5 ± 8.0
NA

TAC, 1 wk
Fhl1–/–

(n = 10)

24.9 ± 3.8
552 ± 58
0.71 ± 0.07
3.36 ± 0.27
0.78 ± 0.16
0.70 ± 0.07
49.9 ± 7.1
NA

WT (n = 12)
27.8 ± 4.32
498 ± 43
0.9 ± 0.09A
3.62 ± 0.41
1.75 ± 0.70
0.89 ± 0.12A
39.8 ± 10.5A
111.2 ± 32.0

Sham, 5 wk
Fhl1–/–

(n = 10)

25.8 ± 3.0
521 ± 76
0.73 ± 0.06
3.43 ± 0.36
1.33 ± 0.50
0.71 ± 0.36
47.1 ± 8.9
95.2 ± 34.5

WT (n = 12)

TAC, 5 wk
Fhl1–/–

28.3 ± 1.7
572 ± 46
0.61 ± 0.05
3.8 ± 0.03
2.1 ± 0.1
0.64 ± 0.03
45.4 ± 3.4
NA

(n = 10)

27.6 ± 1.7
563 ± 50
0.6 ± 0.08
3.7 ± 0.16
1.89 ± 0.60
0.66 ± 0.02
44.0 ± 4.8
NA

WT (n = 13)
31.8 ± 1.8
607 ± 30
0.8 ± 0.05A
4.2 ± 0.04A
2.8 ± 0.3A
1.0 ± 0.06A
26.3 ± 5.1A
90.3 ±16.7

Fhl1–/– (n = 10)
32 ± 1.8
605 ± 45
0.7 ± 0.05
3.95 ± 0.03
2.26 ± 0.20
0.72 ± 0.06
41.5 ± 5.5
82.0 ± 14.5

HR, heart rate; LVIDd, LV internal dimension at end-diastole; LVIDs, LV internal dimension at end-systole; TSPG, trans-stenotic systolic pressure gradient
as the difference between right carotid and left axillary artery systolic pressures. Results are expressed as mean ± SEM. AP < 0.05 between Fhl1–/– and WT
at same point, and P < 0.05 before and after TAC within the same group.

We were able to demonstrate that FHL1 interacts with this minimal
N2B region of titin (Figure 3C). Interaction between titin N2B and
an HA control was not observed (Figure 3C). The colocalization of
Raf1, MEK1/2, and ERK2 with titin N2B was also demonstrated
by immunofluorescence staining of adult cardiomyocytes, which
demonstrated their localization at the I band (Figure 3B).
FHL1 can modulate cardiac MAPK activation. The I band is a region
long thought to be a “hotspot” for signaling (25); however, the
consequences of these recently identified interactions on the signaling cascade remain unclear. Since ERK1/2 activation/phosphorylation is an endpoint of the Raf-mediated MAPK cascade, we
sought to determine the consequences of loss of FHL1 on ERK1/2
activation. Fhl1–/– hearts showed a significant loss in ERK1/2 phosphorylation following TAC (Figure 3D). No significant differences
in basal ERK1/2 phosphorylation were observed between WT and
Fhl1–/– hearts (Figure 3D). Double KO/Gq hearts also demonstrated a significant reduction in ERK1/2 phosphorylation when compared with Gq hearts (Figure 3D). Again, no significant differences
in basal cardiac ERK1/2 phosphorylation were observed between
Fhl1–/–, Gq transgenic, and double KO/Gq mice (Figure 3D). To
determine whether FHL1 is sufficient to modulate ERK1/2 activation in cardiomyocytes, we assessed the effects of FHL1 overexpression on ERK1/2 activation in postnatal cardiomyocytes in vitro.
Overexpression of FHL1 caused a significant increase in ERK1/2
phosphorylation compared with control infected cardiomyocytes
(Figure 3E). No significant differences in Akt phosphorylation
were observed between groups (Figure 3, D and E).
Based on the loss of ERK1/2 activation and hypertrophy (Figure 1G and Figure 3E) in Fhl1–/– hearts following TAC, we sought
to determine the consequences of Fhl1 deficiency on markers of
these parameters in isolated papillary cardiac muscles following
acute stretch (Figure 4A), since it is not possible to directly assess
ERK1/2 activation in these small muscles. ELK1, a transcriptional
target of ERK1/2 activation (26), and ANF, a marker of stretch
and hypertrophy (27), were assessed by quantitative PCR analysis
in isolated papillary muscles stretched for 5 hours at 90%–95%
Lmax (muscle length at which the muscle develops the maximum
force). ELK1 and ANF expression were significantly increased in
stretched WT muscles, while no significant increases in ELK1 or
ANF expression were observed in stretched Fhl1-deficient muscles
(Figure 3F), demonstrating a loss of stretch-induced hypertrophic
signaling responses.


Selective reduction of titin I band associated passive tension in isolated adult
FHL1-deficient muscles after stretch. FHL1 interacts with the cardiac-specific N2B element of titin, which is part of the extensible I band region
of titin that contributes to the myofibrillar passive/diastolic tension
generated upon stretch (25). We assessed passive mechanical properties within isolated Fhl1–/– cardiac muscles by subjecting muscles to a
maximum extension of 15%–20% stretch (Figure 4A). No significant
differences in the cross-sectional area of muscle and sarcomere slack
length were observed between Fhl1–/– and WT muscles (Figure 4B).
However, Fhl1–/– muscles displayed a significant reduction in diastolic
stress (Figure 4C) and therefore increased compliance compared with
controls. An increase in sarcomere length was also observed in Fhl1–/–
muscles when stretched to a diastolic stress of 20 kPa, compared with
WT muscles (Figure 4B). Active mechanical properties, such as developed systolic stress, time to peak contraction, maximum rate of force
production (+df/dt maximum), 90% relaxation time, and maximum
rate of force decline (–df/dt maximum) were not significantly different between Fhl1–/– and WT muscles at Lmax (Figure 4C), suggesting a
specific role for FHL1 in diastolic tension/function.
Discussion
Our studies have identified what we believe is a novel complex within the cardiomyocyte sarcomere that is involved in sensing biomechanical stress and plays a pivotal role in the early events leading
to pathological cardiac hypertrophy. Fhl1 is a member of the newly
identified FHL family, which has long been thought to play an
important role in biomechanical stress responses involved in cardiac
hypertrophy and disease in mice and humans (14–18). Our studies
reveal that under conditions of in vivo pressure overload, Fhl1 deficiency in mice is sufficient to blunt hypertrophy and early progression to heart failure, while preserving cardiac function. Surprisingly,
even though Fhl1–/– mouse hearts did exhibit some hypertrophy in
the long-term TAC studies, this hypertrophy was not associated
with a decrease in cardiac function and is suggestive of a beneficial
form of hypertrophy reminiscent of physiological hypertrophy. In
this regard, it is interesting to note that there are 2 other genetically
altered mouse models that develop limited hypertrophy in response
to chronic pressure overload (8 weeks of TAC), in which little or no
deterioration in cardiac function is observed (28). The effects of Fhl1
deficiency on hypertrophy are not influenced by FHL2, since no differences in FHL2 protein expression were observed between WT and
Fhl1–/– hearts. Also, we previously demonstrated that Fhl2–/– mice do
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Figure 2
FHL1 is linked to the Gq signaling pathway in cardiomyocytes. (A) Fhl1 expression in cardiomyocytes following phenylephrine (PE) and angiotensin II treatment as well as viral Gq overexpression, using a constitutively active Gq virus and Gq transgenic mouse model. Left and middle: RNA
(10 μg) was electrophoresed from control and agonist-/viral-treated cardiomyocytes and analyzed using a cDNA probe spanning the Fhl1 coding
region. GAPDH or 28S RNA was used as a loading control. Right: Protein (25 μg) from WT and Gq+ hearts at 12 weeks of age were subjected to
The Journal of Clinical Investigation
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SDS-PAGE and analyzed for FHL1 (~32 kDa) protein using FHL1 antibodies. GAPDH (~37 kDa) protein was used to normalize for loading.
(B) LV weight/BW ratios in WT, KO, Gq+, and double KO/Gq+ mice
at 12 weeks of age (n = 6). Paraffin sections from Gq+ and KO/Gq+
hearts were stained for nuclei and cytoplasm, respectively, with hematoxylin and eosin. Scale bar: 2.5 mm. (C) Anf, β-MHC, and skeletal
α-actin RNA expression in WT, KO, Gq+, and KO/Gq+ LVs (n = 4)
were normalized for Gapdh expression and presented as fold induction relative to WT. (D) Echocardiographic measurements obtained
from WT, KO, Gq+, and KO/Gq+ LVs at 12 weeks of age. LVIDd, LV
internal dimension at end-diastole. *P < 0.05; **P < 0.01.

specific manner, serving as the molecular backbones for signaling
complex assembly (34, 35). Studies on proteins such as kinase suppressor of Ras (KSR) have identified an important role for scaffold
proteins in regulating MAPK signaling (36, 37). There are several
proposed functions for MAPK scaffold proteins, which include activation of kinases, regulation of the intensity of signaling responses,
recruitment or movement of a complex to a location, consolidation or sequestration of proteins to regulate protein interactions,
or control of protein subcellular localization (38). KSR functions
by regulating the intensity and duration of Raf/MEK/ERK signaling, which could alter cell fate (38). Our results suggest that FHL1
may not only be important in subcellular localization of the MAPK
complex at the I band but also may enhance intensity and duration of MAPK signaling to facilitate hypertrophic signaling, since
increased endogenous interactions were observed between FHL1
and the MAPK cascade components following TAC (a stimulus
known to increase ERK signaling). Although several studies support the role of Raf1 and MEK1/2 in cardiac hypertrophy (39–42),
a recent study that employed gene KO and transgenic approaches
suggested that ERK-mediated phosphorylation is not essential for
cardiac hypertrophy (42). Results of the latter study, performed in
gene KO models (conventional ERK2 heterozygous mice and conventional ERK1 homozygous mice), as the authors point out, leave
open the possibility that the level of residual ERK1/2 activity in
these models could be sufficient to mount a hypertrophic response
and insufficient to accurately determine the effects of a complete
loss of ERK1/2 signaling in hypertrophy. This study, which involved
transgenic overexpression of the MAPK phosphatase DUSP6 also
suggest that ERK1/2 phosphorylation is not involved in hypertrophy (42). However, it is also not clear whether in vivo overexpression of DUSP6 could influence other pathways, which could compensate for the loss of ERK1/2 activity. Our studies demonstrate
that changes in sarcomeric extensibility and intracellular signaling
responses related to ERK1/2 signaling may both contribute to the
abrogration of hypertrophy in Fhl1–/– mice.
Fhl1–/– muscles display increased compliance. Although no significant differences in slack sarcomere length were observed between
WT and Fhl1–/– muscles, an increase in sarcomere length/extensibility was observed in Fhl1–/– muscles when compared with WT
muscles at a similar stress. Since the I band region is the extensible
region of the sarcomere and FHL1 interacts with titin N2B, these
studies further point to a direct role for FHL1 in I band–associated sarcomere extensibility. These findings are different from the

not exhibit any significant differences in the hypertrophic response
following TAC when compared with WT controls (29). Our studies
further demonstrate that FHL1 plays a pivotal role in active relaxation, since Fhl1–/– hearts exhibited increased –dP/dt maximum and
relaxation time constant as well as preserved LV end-diastolic pressure after TAC when compared with WT hearts. Interestingly, loss
of FHL1 also results in beneficial effects on the systolic parameters
within the heart after pressure overload.
FHL1 is a part of what is, to our knowledge, a novel complex within the sarcomeric central I band of titin formed by the direct interaction between FHL1 and the N2B region of titin. Titin is the largest
known cytoskeletal protein and primarily functions as a molecular
spring to provide myofibrils with elasticity (25). Cardiac titin contains a unique cardiac-specific N2B element within the sarcomeric
I band that is thought to act as a biomechanical sensor and contributes to myofibrillar passive tension (diastolic function) generated upon stretch (25, 30). This is consistent with studies in titin
N2B–deficient mice, which demonstrate that the N2B region of titin
affects diastolic but not systolic function of the heart (31). Multiple
mechanisms of titin-based stretch sensing and signaling pathways
have been proposed within the central I band (5, 32). However, our
studies demonstrate an in vivo role for the titin N2B binding partner, FHL1, in diastolic function and biomechanical stress responses
involved in pressure overload–induced hypertrophy.
Our data strongly suggest that FHL1-mediated pathways lie
downstream of Gq signaling, since Fhl1 deficiency in mice completely prevents Gq-mediated cardiomyopathy. In addition, GPCR
agonists or overexpression of constitutively active Gq upregulates
FHL1 expression in postnatal cardiomyocytes in vitro and mouse
hearts in vivo, respectively. FHL1 also intersects with the Gq signaling pathway by directly interacting with downstream signaling
components Raf1, MEK2, and ERK2. Our studies further demonstrate a role for FHL1 as an endogenous
Table 2
positive regulator of Raf-1/MEK/ERK–mediated sigQuantitative β-galactosidase assays for domain interactions between FHL1 and
naling. This was most clearly evidenced when FHL1
Raf1, MEK1/2, and ERK2
overexpression was sufficient to increase cardiomyocyte ERK1/2 phosphorylation and by the blunted
Raf1
MEK1
MEK2
ERK2
ERK2 (TYDD)
response to ERK1/2 phosphorylation in Fhl1–/– cardiA
A
A
1
±
0.3
33
±
3.1
39
±
3.8
58 ± 2.6A, B
FHL1
(4.5
LIM)
49
±
2.6
ac muscles following TAC and in the background of
FHL1
(3.5
LIM)
25
±
1.2
1
±
0.2
18
±
2.4
26
±
1.5
28 ± 1.3
Gq overexpression in vivo. The Gq signaling pathway
FHL1 (2 LIM)
20 ± 2.6
1 ± 0.4
19 ± 2.4
19 ± 2.7
26 ± 1.2
has been shown to target ERK activation under condiFHL1 (1.5 LIM)
1 ± 0.2
2 ± 0.6
1 ± 0.2
1 ± 0.3
1 ± 0.3
tions of in vivo pressure overload (33).
FHL1 (Kyot2)
1 ± 0.3
1 ± 0.3
1 ± 0.2
1 ± 0.2
1 ± 0.3
FHL1 could also fulfill a scaffolding function, since
direct interactions between FHL1 and Raf-mediated
One unit of β-galactosidase was defined as the amount of enzyme that hydrolyzes 1
μmol of ortho-nitrophenyl-β-d-galactopyranoside (ONPG) to O-nitrophenol and d-galacMAPK cascade converge at the N2B region of titin.
tose per minute per cell. The results from 4 separate measurements are expressed as
Scaffolding proteins are dynamic entities that can regmean ± SEM. AP < 0.01, full-length FHL1 (4.5 LIM) versus truncated FHL1 forms.
ulate signal transduction pathways by tethering molBP < 0.01, interaction of full-length FHL1 (4.5 LIM) and ERK2 versus full-length FHL1
(4.5 LIM) and ERK2 (TYDD).
ecules together in a subcellular location and stimulus

The Journal of Clinical Investigation

http://www.jci.org

Downloaded on August 16, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/34472

research article

Figure 3
FHL1 associates with and affects the MAPK pathway. (A) Raf1 (left), MEK1/2 (middle), and ERK2 (right) were immunoprecipitated from 8-weekold adult mouse heart extracts (500 μg) following sham and TAC (1 week) operation and western blot analysis for FHL1 (~32 kDa), Raf1 (~80 kDa),
MEK1/2 (~47 kDa), and ERK2 (44 kDa) proteins as indicated. Plus and minus symbols indicate the presence and absence of antibody. Molecular
weight standards are indicated on Ponceau S–stained membranes. (B) Adult cardiomyocytes were stained with antibodies against FHL1, Raf1,
MEK1/2, ERK2, and titin N2B. Merged images of doubly stained cardiomyocytes are shown. Scale bar: 2 μm. Double arrows indicate colocalization. (C) COS cells were cotransfected with GFP-htitinN2B and HA-tagged FHL1 or FHL2 or control. Coimmunoprecipitation was carried out with
an anti-HA antibody, followed by detection of the GFP fusion protein (~80 kDa) with GFP antibodies. “Input” indicates non-fractionated protein
prior to coimmunoprecipitation assay. (D) Western blot analysis of phosphorylated and total ERK1/2 (42 and 44 kDa) and Akt (60 kDa) in WT
and KO adult mouse hearts after sham or TAC operation for 7 days (top); KO, Gq+, and KO/Gq+ mouse hearts (12 weeks old; bottom); and (E)
lacZ and FLAG-FHL1 viral treatment of neonatal cardiomyocytes for 24 hours. Expression of the FLAG-FHL1 virus was confirmed with FLAGand FHL1-specific antibodies. (F) RT-PCR analysis of Anf and Elk1 expression in isolated WT and KO muscles (n = 5) before stretch (UnStr)
and after stretch (Str). *P < 0.05; **P < 0.01.
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Figure 4
Muscle mechanics within isolated adult WT and Fhl1-deficient cardiac muscles following stretch. (A) Schematic representation of isolated adult
RV papillary mouse muscle from 8- to 12-week-old mice in a tissue chamber. Specimens were stretched for 5 hours to a maximum extension
of 15%–20% (90%–95% Lmax). Control muscles were left in the system for the same period of time at slack length. The system was used to
analyze load-inducible hypertrophic markers as well as passive and active stresses as a function of passive stretch. (B) Quantitative assessment of cross-sectional area and slack sarcomere lengths in WT and Fhl1-deficient muscles. (C) Passive tensile stress (diastolic stress) of RV
papillary muscles in WT and KO muscles before and after stretch. Sarcomere lengths in WT and KO muscles at 20 kPa stress. *P < 0.05. (D)
Active mechanical properties were assessed in isolated WT and KO muscles as a function of stretch.
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Figure 5
Working model for the pathways that link
defects in the MAPK/FHL1/titin complex to
cardiac sarcomere extensibility and hypertrophic signaling. Left: FHL1 is a component of the stretch sensor at the I band that
acts to sense stretch or agonists induced
by GPCR (Gq) signaling to restrict or lock
the range at which physiological sarcomere length can extend following stretch
and/or to scaffold Gq/stress-induced interactions of MAPK components at titin N2B
in order to mediate ensuing hypertrophic
signaling, which can lead to pathological
cardiac hypertrophy. Right: Loss of FHL1
leads to unlocking and/or destabilization of
the macromolecular MAPK/FHL1/titin complex in cardiomyocytes, thereby resulting
in increased passive elasticity and sarcomere extensibility and/or loss of the ability
to scaffold Gq/stress-induced interactions
of MAPK at the I band, resulting in reduced
hypertrophic signaling and a blunted
response to cardiac hypertrophy.

results of studies in MLP- and titin N2B–deficient mice, in which
the reduced passive tension and basal cardiac muscle defects
were likely due to shortened sarcomere slack lengths (4, 31, 32).
Extracellular collagen is one of the major contributors to myocardial diastolic tension at longer sarcomere lengths (43). However,
no obvious changes in collagen content, as assessed by Masson’s
trichrome stain, were detected in Fhl1–/– hearts compared with
those of controls (our unpublished observations), further pointing to an influence of titin on passive mechanics in Fhl1–/– mice.
In conclusion, our studies propose a working hypothesis whereby
FHL1 plays an important role in the general mechanism of pathological hypertrophy by sensing biomechanical stress responses in
the sarcomere via the titin N2B region, thus leading to changes in
MAPK- and titin-mediated responses, which are important for the
transition to pathological hypertrophy (Figure 5). The N2B region of
titin extends mostly toward the upper limit of the physiological sarcomere length of cardiac muscle (25, 44). Our findings highlight what
we believe is a novel role for FHL1 in modulating titin N2B function
and sarcomere extensibility at the upper limits of the physiological
sarcomere length, a state that could be physiologically reached in
vitro through acute stretch and in vivo by pressure overload. Since
Fhl1 deficiency is sufficient to prevent the deleterious effects following Gq overexpression in vivo, these studies further suggest that the
MAPK/FHL1/titin complex is a key target of Gq signaling. A recent

study has identified a titin N2B mutation associated with hypertrophic cardiomyopathy in a region that specifically binds and modulates FHL affinity (45), suggesting the possibility that destabilization
of the macromolecular titin/I band complex including FHL1 could
also potentially underlie genetic forms of cardiomyopathy. A better
understanding of the role of FHL1 in titin and Gq/MAPK signaling
in striated muscle in vivo could be of critical importance in developing strategies (i.e., inhibitors of FHL1) to abolish the deleterious
effects of pathological hypertrophy in human cardiac disease.
Methods
Generation of gene-targeted and transgenic mice. Fhl1 genomic DNA was isolated from a 129-SV/J mouse genomic DNA library (Stratagene). PCRbased mutagenesis was used to convert the approximately 350-bp sequence
between 2 bp 5′ of the translation start codon ATG in Fhl1 exon 1 (the
first coding exon) and 2 bp 5′ of the EcoRI site in intron 1 to a SalI site.
The deleted 350-bp fragment would contain part of Fhl1 exon 1 and part
of intron 1. A LacZ/pGKneo cassette was inserted into the SalI site using
XhoI, thereby destroying the SalI site. The targeting construct was linearized
with SstII before electroporation into RI ES cells. G418-resistant ES clones
were screened for homologous recombination by BamHI digestion, followed
by Southern blot analysis, as previously described (8). Two independent
homologous recombinant ES clones were microinjected into C57BL/6J
blastocysts and transferred into pseudopregnant recipients. Chimeric ani-
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mals resulting from the microinjection were bred with Black Swiss mice to
generate germ line–transmitted agouti heterozygous female mice (Fhl1+/–)
or hemizygous male (Fhl1–/y) mice. Fhl1 localizes at the X chromosome, and
because large numbers of WT littermate and Fhl1–/– mice could be attained
per litter, all of our experiments were performed on male mice. Offspring
from Fhl1 intercrosses were genotyped by PCR analysis. PCR analysis was
performed on tail DNA from mouse offspring from Fhl1 intercrosses by
using Fhl1 WT allele– (forward, ACCATGTCGG AGAAGTTCGACT; reverse,
AGGCTGCAGGTATACACCTGAA) as well as Fhl1 KO allele–specific primers (forward, CCTCTGAGTCAGCAGCGTGATT; reverse, AGATGAAACGCCGAGTTAACGC) using standard procedures. Genotypes for Gq mice
were determined using tail DNA and Gq transgene–specific primers (forward, CAGGACTTCACATAGAAGCC; reverse, CGTGAAGATGTTCTGATACACC) using standard procedures. Fhl1 hemizygous KO mice (Fhl1–/y)
were also mated with Gq-40–overexpressing mice (22) to generate hemizygous FHL1 offspring carrying the Gq transgene (KO/Gq). F1 KO/Gq mice
were bred to heterozygous Fhl1 littermates lacking the transgene in order
to obtain F2 mice with 5 different genotypes — WT, Gq gain-of-function
transgenic (Gq+), Fhl1 hemizygous KO, and the combinatorial genotypes
(Fhl1 hemizygous KO/Gq+ and Fhl1 heterozygous KO/Gq+) — within the
same litter. Comparisons were only made within litters, which contained
KO, Gq+, KO/Gq+, and age-matched WT littermate controls, and thus utilizing only male animals made the breeding process much easier. All animal
procedures were approved by the UCSD Animal Care and Use Committee.
Protein blot analysis. Total protein extracts were prepared as previously
described (8). Polyclonal antibodies to FHL1 were produced in rabbits immunized with a synthetic KLH-conjugated peptide corresponding to mouse FHL1
protein (DPLQGKKYVQKDGR) and were used for immunodetection of
FHL1 (1 μg/ml; Chemicon International). Immunodetection of FHL2 (1:1000;
a kind gift from Beat Schäfer, Institute of Cell Biology, ETH Hönggerberg,
Zurich, Switzerland), glyceraldehyde-3-phosphate dehydrogenase (1:1000;
Cell Signaling Technology), elongation factor-1α (1 μg/ml; Chemicon International), phospho-ERK1/2 (1:1000; Cell Signaling Technology), total ERK1/2
(0.5 μg/ml; Upstate USA Inc.), phospho-Akt (Ser473) (1:1000; Cell Signaling
Technology), total Akt (1:1000; Cell Signaling Technology), and FLAG (10 μg/ml;
Sigma-Aldrich) was performed as previously described (27).
Histological and morphometric analyses. Cardiac sections (8 μm thick) were
stained with hematoxylin and eosin as previously described (8). Cardiac
sections were immunostained with fluorescein-conjugated wheat germ
agglutinin (Invitrogen) and stained for DNA with Hoechst 33342 to measure myocyte area at ×400 magnification (Olympus).
In vivo pressure overload model. Adult mice (8–10 weeks old) were anesthetized with ketamine/xylazine, and TAC was performed as previously
described (46).
Hemodynamic and blood pressure measurements. Please see Supplemental
Methods for details.
RNA analysis. Total RNA was extracted from LVs, cardiomyocytes, and
papillary muscles using TRIzol (Invitrogen) or RNeasy (Qiagen). Dot blot
and northern blot analyses were performed as previously described (14, 47).
Quantitative PCR was performed using the ABI 7700 real-time thermal
cycler using standard procedures.
Echocardiography. Adult mice were anesthetized with 1% isoflurane and
subjected to echocardiography as previously described (48).
Cardiomyocyte cultures and treatments/infections. Cardiomyocytes were prepared from 1- to 2-day-old neonatal rats as previously described (27) and
treated with phenylephrine (0.1 mM) or angiotensin II (100 nM) for 24 h.
Cardiomyocytes were treated with PD98059 (50 μM/l), SB203580 (10 μM), or
wortmannin (10 μM/l) in the presence of phenylephrine (0.1 mM) or angiotensin II (100 nM). Adenovirus vectors containing the lacZ and mouse Fhl1
cDNAs were prepared and used at multiplicity of infection 25–50 pfu/cell
10

as previously described (27). The constitutively active Gq adenovirus
(Q209L) was previously generated and was used in cardiomyocytes as previously described (49).
Yeast 2-hybrid assays. Yeast 2-hybrid and β-galactosidase assays were carried
out according to manufacturer’s instructions (Clontech). To assay the interaction between FHL1 with Raf-1, MEK1, MEK2, ERK2, and ERK2 (TYDD), the
coding sequences for full-length FHL1 (4.5 LIM), the small isoform of FHL1
(KyoT2), and the deletion mutants FHL1 (3.5 LIM), FHL1 (2 LIM), and FHL1
(1.5 LIM) were generated by PCR and were subcloned into the pLexA bait vector
(50). The coding sequences for Raf1, MEK1, MEK2, ERK2, and ERK2 (TYDD)
were generated by PCR and subcloned into the vector pACT2 (Clontech). ERK2
(TYDD) was generated by PCR-based mutagenesis (Quikchange; Stratagene).
Two plasmids were cotransformed into the yeast strain L40 and assayed for
β-galactosidase activity and for growth on selection plates lacking the amino
acids tryptophan, leucine, and histidine (51). Four independent positive L40
yeast colonies per protein-protein interaction were assessed for β-galactosidase
activity using the ortho-nitrophenyl-β-d-galactopyranoside–driven (ONPGdriven) liquid culture method as described by the manufacturer (Clontech).
Primers and templates for PCR are described in Supplemental Table 3.
Immunoprecipitation assays. Protein extracts were isolated and prepared as
previously described (24). Raf1 (Santa Cruz Biotechnology Inc.), MEK1/2
(Cell Signaling Technology), and ERK2 (BD) antibodies were used for
immunoprecipitation according to the manufacturers’ instructions,
followed by SDS-PAGE and immunodetection of FHL1 (1 μg/ml). For
immunoprecipitation assays in COS-1 cells, plasmids encoding HA-tagged
DRAL/FHL2 (HA-DRAL), HA-tagged FHL1 (HA-FHL1), and HA-tagged
p62 control were cotransfected with GFP-tagged human cardiac titin N2B
us3 (residues 3,794–4,064 of the cardiac N2B isoform; NCBI accession no.
X90568; ref. 52) into COS-1 cells. The HA-tagged DRAL/FHL2 and FHL1
constructs have been previously described (24). Cells were harvested 24–48
hours later and were immunoprecipitated with monoclonal HA antibodies (1:100; Roche) and processed for SDS-PAGE and GFP (1:1000; Roche)
immunodetection as previously described (24).
Immunofluorescence microscopy. Adult cardiomyocytes were isolated (53)
and incubated in a relaxation buffer (24), fixed with 4% paraformaldehyde,
and stained with primary antibodies against FHL1 (1:50), Raf1 (1:200;
Santa Cruz Biotechnology Inc.), ERK2 (1:100; BD), MEK1/2 (1:25; Cell Signaling Technology), and titin N2B (1:2; a kind gift from Mathias Gautel,
King’s College London, London, United Kingdom). Cells were then stained
with secondary antibodies (1:250; Invitrogen), followed by visualization of
signals by confocal imaging (BioRad Radiance 2000).
In vitro cardiac muscle model of load-induced hypertrophy. Please see Supplemental Methods for details.
Sarcomere length analysis. Mechanically unloaded RV papillary muscles
were fixed with 4% paraformaldehyde in relaxing solution for 1 hour at
4°C. Muscle cryosections (5 μm thick) were stained with primary antibodies against sarcomeric α-actinin (1:200; Sigma-Aldrich), followed by
secondary antibody staining (1:400; Invitrogen). Sarcomere lengths were
visualized by confocal microscopy (BioRad Radiance 2000) and measured
by FFT analysis (MATLAB) for sarcomere periodicity.
Statistics. Data presented in the text and figures are expressed as mean
values ± standard error of the mean. Significance was evaluated by the
2-tailed Student’s t test or repeated-measures ANOVA. Statistical analysis
for muscle mechanics data is described in detail in the Supplemental Methods. P < 0.05 was considered statistically significant.
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